PERTH, Australia - The U.S. Federal Trade Commission has authorized a lawsuit to stop Australian-based CSL Limited's $3.1 billion acquisition of Talecris Biotherapeutics, charging that the deal "would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies," the commission announced May 27
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.
Multi-blockbuster falls short in a giant cell arteritis study.
